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Abstract
Background: Eosinophils are effector cells during parasitic infections and allergic responses. However, their contribution to
innate immunity has been only recently unravelled.
Methodology/Principal Findings: Here we show that human eosinophils express CD3 and cd T Cell Receptor (TCR) but not
ab TCR. Surface expression of cdTCR/CD3 is heterogeneous between eosinophil donors and inducible by mycobacterial
ligands. Surface immunoprecipitation revealed expression of the full cdTCR/CD3 complex. Real-time PCR amplification for
CD3, c and d TCR constant regions transcripts showed a significantly lower expression in eosinophils than in cdT cells.
Limited TCR rearrangements occur in eosinophils as shown by spectratyping analysis of CDR3 length profiles and in situ
hybridization. Release by eosinophils of Reactive Oxygen Species, granule proteins, Eosinophil Peroxidase and Eosinophil-
Derived Neurotoxin and cytokines (IFN-c and TNF-a) was observed following activation by cdTCR-specific agonists or by
mycobacteria. These effects were inhibited by anti-cdTCR blocking antibodies and antagonists. Moreover, cdTCR/CD3 was
involved in eosinophil cytotoxicity against tumor cells.
Conclusions/Significance: Our results provide evidence that human eosinophils express a functional cdTCR/CD3 with similar,
but not identical, characteristics to cdTCR from cdT cells. We propose that this receptor contributes to eosinophil innate
responses against mycobacteria and tumors and may represent an additional link between lymphoid and myeloid lineages.
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Introduction
Eosinophils are polymorphonuclear granulocytes mainly found
in increased numbers during helminth parasitic infections and
allergic reactions [1,2]. They are classically considered as
mediator-releasing cells during effector phase of adaptive immu-
nity, under the influence of T cell dependent cytokines or
chemokines and antibodies [2], whereas eosinophil-derived
chemokines have been recently shown to locally attract Th2
lymphocytes at lung inflammatory sites [3,4]. Nevertheless, their
precise function as beneficial or deleterious to the host still remains
ambiguous, since highly toxic proteins present in eosinophil
granules exert potent cytotoxic effects against non self targets such
as parasites [5,6] but also against stressed or necrotic host cells [7]
and in asthma [8]. Eosinophils are foremost present in mucosal
tissues in contact with the environment such as in gastro-intestinal
tract and skin [2] and are characterized by their wide
morphological and functional heterogeneity [9].
In addition to these effector functions, eosinophils produce
several Th1, Th2 and regulatory cytokines, such as IL-10 [10,11],
which, in contrast to T cells, are stored within granules and
promptly released upon activation [12]. Eosinophils also express
MHCII and CD86 [10,13,14] and act as antigen-presenting cells
[15]. Furthermore, eosinophils share with T cells expression of
various receptors such as CD25 [16,17], CD4 [18], CD28 [10,14]
and several members of the CD2 family, including 2B4 [19]. This
wide array of molecules endows eosinophils with the ability to
induce and regulate adaptive immunity.
However, the early appearance of eosinophils in agnathans,
predating the appearance of the classical adaptive immune system
[20] and the expression by eosinophils of several receptors
involved in innate immunity, such as formyl peptide receptor
[21], protease-activated receptors [22,23] and TLR [24] further
point toward a role for eosinophils in innate immunity. Eosinophils
contribute to TLR-mediated immunity against viruses and
mycobacteria [25,26]. Indeed, we recently showed that TLR-2-
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5926dependent activation of human eosinophils induced a-defensin
and ECP release and decreased mycobacteria growth [24].
Furthermore, expulsion of mitochondrial DNA by eosinophils
has been shown to contribute to innate immune defences against
bacteria [27]. Finally, eosinophil-tumor cell interactions and IL-4-
dependent tumoricidal activity of eosinophils have been reported
[28,29]. Thus eosinophils appear functionally located at the
interface between innate and adaptive immunity.
Strikingly, cdT cells are ancestral to other lymphoid populations
such as abT cells and B cells, they participate to both innate and
adaptive immune responses, have a preferential mucosal localisa-
tion and might act as professional antigen-presenting cells [30]
recognizing non-peptide antigens found on several pathogens,
including mycobacteria, necrotic and tumor cells [31,32].
These surprising similarities between cdT cells and eosinophils
prompted us to investigate, whether, in addition to other T cell-
associated receptors, human eosinophils expressed a cdT cell
Receptor (TCR). We here report that human blood eosinophils
express low levels of surface cdTCR/CD3, inducible by
mycobacterial ligands. We show that eosinophils release granule
proteins and cytokines upon activation by cdTCR agonists,
including mycobacteria. Furthermore, we provide evidence that
cdTCR contributes to eosinophil cytotoxic potential towards
tumors.
Results
Human eosinophils express CD3 and cdTCR but not
abTCR
In order to investigate expression by human blood eosinophils
of T cell associated receptors, we purified eosinophils by negative
selection using magnetic beads. These highly purified eosinophils
(Figure S1A) expressed specific granule proteins such as eosinophil
peroxidase (EPO) and major basic protein (MBP) but not
myeloperoxidase (MPO) associated to neutrophil and monocyte/
macrophage lineages [33] (Figure S1B). Lymphocytes expressed
neither of these myeloid markers (Figure S1B).
Following permeabilization, binding of anti-CD3 but not anti-
CD8 antibodies was detected in eosinophils (Figure 1A). In T cells,
CD3 associates with either abTCR or cdTCR. We did not detect
abTCR on eosinophils but cdTCR expression was evidenced
(Figure 1A). While lymphocytes from PBMC fraction expressed
these markers at the expected frequencies (Figure 1B) and unlike a
previous report [34], we were unable to detect CD3 or abTCR
expression in neutrophils (Figure 1C). Likewise neither CD8 nor
cdTCR expression was detected in neutrophils (Figure 1C).
Surface expression of CD3 and cdTCR was detected on a
fraction of eosinophils following double staining with antibodies
against two specific eosinophil granule proteins EPO (Figure 2A)
or MBP (Figure 2B). Similarly to intracellular staining, neither
CD8 nor abTCR were detected at eosinophil surface. By contrast,
another cdT cell marker, NKG2D, was expressed in a lower
proportion of cells (Figure 2A–B). As CD3 is required for receptor
complex surface expression, CD3
+cdTCR
+ eosinophils were thus
identified following triple staining (Figure 2C). In human blood,
cdT cells express either Vc9/Vd2o rV d1 variable regions. We
also evidenced that EPO
+ or MBP
+ eosinophils expressed Vc9,
Vd1 and Vd2 and unexpectedly co-expressed Vd1 and Vd2a t
their surface (Figure 2A–C).
Expression of cdTCR/CD3 complex was investigated in
healthy donors and patients with either reactive eosinophilia
(allergies, various skin diseases) or hypereosinophilic syndrome
(HES). A wide heterogeneity of surface expression of cdTCR/
CD3 and NKG2D was not only found among the 23 donors but
also within each group, including healthy donors, however no
correlation was observed between receptor expression levels and
either eosinophilia, or a specific pathology (Figure 3A–B).
Following in vitro activation of cdT cells, CD3, CD8, cdTCR as
wellasVc9,Vd2an dV d1weredetectedattheexpectedfrequencies
(Figure S2A). Likewise, freshly isolated PBMC from the same
eosinophil donors, in which cdT cells represent a very minor
population,expressedCD3,abTCRorlowlevelsofcdTCR(Figure
S2B). By contrast, monocytes did neither express CD3 nor cdTCR
(Figure S2C). Finally, neutrophils neither expressed CD3, cdTCR
nor the full abTCR complex at their surface (Figure S2D). Thus,
following overnight culture, a fraction of eosinophils, unambigu-
ously identified by the presence of specific eosinophil markers,
express the cdTCR/CD3 complex at their surface.
Besides receptor reexpression at the membrane following a
resting period, as demonstrated for NKG2A on cdT cells [35],
ligand-dependent induction or upregulation of receptor surface
expression has been widely reported, including in the case of
FceRI [9]. Thus, we investigated whether a specific cdTCR ligand
was able to induce cdTCR/CD3 surface expression on human
eosinophils. While CD3 and cdTCR were barely detected at the
surface of freshly purified eosinophils (Figure S3A), upon
incubation for 2 h with TUBag1, a natural non peptidic ligand
from Mycobacterium tuberculosis [36], about 50% of eosinophils
expressed CD3 and cdTCR at their surface (Figure S3B). By
contrast, neither CD8 nor abTCR expression was induced upon
incubation with TUBag (Figure S3B).
Finally, besides mature eosinophils present in peripheral blood,
eosinophils can be differentiated in vitro from CD34
+ cord blood
progenitors. In such EPO
+ eosinophils, in the absence of possible
contamination by cdTc e l l s ,cdTCR/CD3 complex was detected at
cell surface, after 3 weeks differentiation (Figure S4). As for blood
eosinophils, neither CD8 nor abTCR (not shown) could be detected.
Eosinophils express all the subunits from cdTCR/CD3
complex
To evidence the cellular distribution of cdTCR/CD3 complex
and to further exclude that results obtained by flow cytometry could
be due to contaminating cdT cells, blood eosinophils were analysed
at low magnification by immunofluorescence and at high
magnification by confocal microscopy. In full agreement with flow
cytometry data, in a preparation without contaminatingcells, only a
fraction of blood eosinophils, identified by their typical binucleated
morphology, expressed the four chains of CD3 and cdTCR. No
signal was detected with anti-aTCR, anti-bTCR antibodies or
control IgG (Fig 4A). We next characterized the structure of the
cdTCR/CD3complexexpressedatthe surface ofeosinophils,using
surface biotinylation, followed by lysis with a mild detergent, co-
immunoprecipitation with an anti-cdTCR antibody, SDS-PAGE in
reducing conditions and detection of biotinylated proteins. Bands
corresponding to TCR, CD3d, e, c and f subunits were detected at
the expected molecular weights both on cdT cells and eosinophils
(Figure 4B). This result indicates that all the necessary chains are
present to allow for surface expression of a complete cdTCR/CD3.
However, the amount of material used for eosinophils was 10 times
higher than for cdT cells, results consistent with flow cytometrydata
showing much lower surface expression in eosinophils than in cdT
cells (Figure 2 and Figure S2).
cdTCR/CD3 is less abundant and more restricted in
eosinophils than in cdT cells
Transcripts specific for the four chains (e, f, c and d) of CD3
complex, cTCR and dTCR constant regions and CD8 were
Eosinophil cdTCR Expression
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5926Figure 1. Expression of cdTCR/CD3 complex by human eosinophils. (A–C) CD3, CD8, abTCR and cdTCR expression on permeabilized cells
gated as described in Figure S1 (A) purified peripheral blood eosinophils (B) lymphocytes and (C) neutrophils. Staining with control isotype matched
antibodies is represented in white histograms.
doi:10.1371/journal.pone.0005926.g001
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PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e5926Figure 3. Heterogeneity of surface expression of cdTCR/CD3 complex by human eosinophils. (A) Cell surface marker expression on EPO
+
gated peripheral blood eosinophils from 23 individual eosinophil donors. Group average expression for the indicated markers is represented (-). (B)
Individual data and patient status.
doi:10.1371/journal.pone.0005926.g003
Figure 2. Surface expression of cdTCR/CD3 complex by human eosinophils. (A–C) CD3, cdTCR, Vc9, Vd2, Vd1, abTCR, CD8 and NKG2D
surface expression on EPO
+ (A) and MBP2
+ (B) purified peripheral blood eosinophils analysed after 18 h culture and gated as described in Figure S1.
Results in (A) and (B) represent to 2 distinct representative donors. Staining with control isotype antibodies is represented. (C) Presence of
CD3
+cdTCR
+EPO
+ and Vd1
+d2
+EPO
+ eosinophils identified by triple staining. Staining with control isotype matched antibodies as well as
corresponding double stainings is represented.
doi:10.1371/journal.pone.0005926.g002
Eosinophil cdTCR Expression
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to homogeneity (100%) and cdT lymphocyte subsets or Colo-205
colon carcinoma cells as positive and negative controls respective-
ly. Expression of the various chains was 300 to 4,000 fold lower in
eosinophil population than in cdT lymphocyte population, while
CD8 expression was absent in eosinophils but present in cdT
lymphocytes (Figure 5A). Amplification of Vd1-Jd3, Vd2-Cd and
VcI-JcP rearranged transcripts but not Vd1-Jd4 was also detected
Figure 4. Immunolocalization and Subunit composition of surface-expressed cdTCR/CD3 complex on human eosinophils. (A)
Immunofluorescence and confocal microscopy (insets) analysis of cdTCR/CD3 chains expression on cytospin eosinophil preparations after 18 h
culture. Staining with anti-aTCR, anti-bTCR antibodies and control goat IgG is represented. Arrowheads indicate some positive cells. (B) Surface of
eosinophils and cdT cells was biotin-labelled. Cells were lysed and complexes were immunoprecipitated, using anti-cdTCR or isotype control
antibodies. Immunoprecipitated proteins were resolved on a reducing 14% SDS-PAGE and transferred to PVDF membrane. Biotinylated proteins were
revealed using ABC-HRP and chemiluminescence. Positions of the TCR and CD3 subunits are marked. Material corresponding to the total and to 1/
10
th of the material was loaded for eosinophils and cdT cells respectively. Dashed lines indicate that non adjacent lanes of the same gel have been
joined on the Figure.
doi:10.1371/journal.pone.0005926.g004
Eosinophil cdTCR Expression
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lymphocytes but neither in abT lymphocytes nor Colo-205 cells
(Figure 5B). Spectratyping analysis of CDR3 length profiles for
Vc9-Jc1/2, Vc9-JcP and Vd2-Cd evidenced a limited Vd2-Cd
diversity (2 peaks) on eosinophils compared to cdT cells
(Figure 5C), while no signal was detected on eosinophils for the
2 other rearrangements, in contrast to cdT cells (data not shown).
Furthermore, to unambiguously demonstrate that TCR rear-
rangements occur in eosinophils, at single cell level, we performed
in situ hybridization using sequences from rearranged TCR genes
as RNA probes. Hybridization with anti-sense probes correspond-
ing to Vd2-Cd and VcI-JcP rearrangements, that were detected by
RT-PCR, gave a positive signal on nuclei from eosinophils at times
clearly bilobed. In keeping with RT-PCR results, a significantly
stronger signal was detected on cd T lymphocytes, while
corresponding sense probes only gave background amplification
on both cell types (Fig. 5D). Vd1-Jd4 anti-sense probe gave positive
signal on cd T lymphocytes but not on eosinophils in which this
rearrangement was not detected by RT-PCR.
Finally, DNA sequencing of Vd1Jd3V d2-Cd regions from
eosinophils and cdT cells show that V and J regions were virtually
identical to the IMGT sequence, while significant differences
between eosinophils and 2 different cloned sequences of cdT cells
from the same donor were found in D regions and in junctional
regions (Figure 6). This further confirms that cdTCR/CD3
complex expressed by eosinophils is less expressed and diverse
than the corresponding receptor on cd T cells.
cdTCR/CD3-mediated eosinophil activation induces ROS
production, degranulation and cytokine release
Upon activation, eosinophils very rapidly produce Reactive
Oxygen Species (ROS) and release, by selective degranulation,
eosinophil-specific granule proteins, including highly cytotoxic
cationic proteins such as EPO and eosinophil cationic protein
(ECP) [6]. In purified blood eosinophils, cdTCR/CD3 complex
activation by immobilized antibodies to CD3, cdTCR or Vd1 led
to a similar kinetics of ROS production (Figure 7A) and to a
significant EPO and eosinophil-derived neurotoxin (EDN) release
(Figure 7D and G). Stimulation with a soluble ligand, bromohy-
drin pyrophosphate (BrHPP), a phosphoantigen agonist selective
for human c9d2
+ T lymphocytes [37], induced dose-dependent
ROS production as well as EPO release (Figure 7B and E).
Furthermore, eosinophil activation by sec-butylamine (SBA) [38],
an inducer of endogenous phosphoantigens, yielded to a sustained
dose-dependent ROS and EPO production (Figure 7C and F),
comparable to values obtained following activation with IgA/anti-
IgA immune complexes, one potent physiological eosinophil
activator. Of note, plate-bound antibodies induced stronger
ROS release but weaker EPO release than soluble cdTCR
activators. Since eosinophils also release several immuno-regula-
tory and proinflammatory cytokines [10], we further show that
activation with anti-CD3, -cdTCR or -Vd1 antibodies efficiently
induced IFN-c and TNF-a production by eosinophils (Figure 7H
and I). Thus, cdTCR/CD3-expressing eosinophils respond to
selective agonists similarly to human cdT lymphocytes and
produce both specific eosinophil granule proteins, myeloid cell
mediators as well as cytokines.
Mycobacterium bovis induce cdTCR/CD3-dependent
eosinophil activation
Human cdT cells respond to non-peptide antigens including
mycobacterial and tumor-derived ligands. Patients with mycobac-
terial infections may exhibit blood and tissue eosinophilia and
mycobacteria-induced eosinophil-associated experimental acute
inflammation [39] as well as rapid eosinophil chemotaxis in vivo.
Mycobacteria- eosinophil interactions might thus reflect the
reactivity conferred by cdTCR/CD3 complex. Accordingly,
incubation of blood eosinophils with increasing ratios of
Mycobacterium bovis-BCG induced dose-dependent ROS production
and EPO release (Figure 8A–B), that could be inhibited, in a dose-
dependent manner, by an anti-cdTCR antibody [40] (Figure 8C–
D). Similar eosinophil activation, and inhibition by an anti-
cdTCR antibody, was also obtained following incubation with
TUBag, a natural mycobacterial component (Figure 8E–H). Thus
mycobacteria appear capable of activating eosinophils, at least
partly, in a cdTCR-dependent manner.
cdTCR/CD3-dependent eosinophil cytotoxicity toward
tumor cells
Eosinophils have been associated with many tumors in vivo.
Furthermore, both cd T cells [41] and eosinophils [19] exert
potent cytotoxic activity towards many tumor cells. Therefore, we
investigated cdTCR-mediated eosinophil cytotoxicity towards
Colo-205 carcinoma cell line. Indeed, eosinophils induced time-
dependent apoptosis of Colo-205 tumor cells in vitro, which was
significantly inhibited following addition of neutralizing anti-
cdTCR Ab (Figure 9A). This effect was more prominent at earlier
time-points suggesting that cdTCR-mediated eosinophil-tumor
interactions are important for the initiation of the cytotoxic
reaction (Figure 9B). Finally preincubation of eosinophils with
cdTCR ligands, SBA and TUBag, potentiated eosinophil
cytotoxicity towards tumor cells (Figure 9C–D). Altogether, these
data confirm the potential role of eosinophils in anti-tumor
cytotoxicity and strongly suggest the involvement of cdTCR/CD3
complex in this mechanism.
Discussion
We here provide evidence that highly purified human blood
eosinophils, as well as eosinophils differentiated in vitro from
CD34
+ cord blood progenitors, gated on the basis of presence of
specific eosinophil granule proteins, express a functional cdTCR/
CD3 complex, so far almost exclusively associated to T
lymphocytes, but lack abTCR. As previously observed for other
receptors such as CD25 [42], CD4 [18], FceRI, CD89 and CD28
[10], cdTCR/CD3 surface expression on eosinophils is highly
heterogeneous between individual donors. Such an heterogeneity
in cdTCR/CD3 expression has also been observed for human
blood cdT lymphocytes [35]. As it is the case for several receptors,
including FceRI [9], surface expression of cdTCR/CD3 can be
Figure 5. cdTCR/CD3 complex expression and rearrangements in human peripheral blood eosinophils. (A) Real time PCR analysis of
expression of individual chains from cdTCR/CD3 complex in eosinophils, cd T cells and Colo-205 cells. Average expression in Colo-205 cells is chosen
as reference (samples were analysed in triplicate using primers listed in Table S1). (B) TCRc and d rearrangements in peripheral blood eosinophils
analysed by RT-PCR using primers listed in Table S2. CD8 amplification is performed to exclude lymphocyte contamination. Colo-205 are chosen as
negative control (C) Spectratyping analysis of CDR3 length profiles for Vc9-Jc1/2 ; Vc9-JcP and Vd2-Cd families in eosinophils and in cd T cells from
the same donor. (D) Expression of rearranged c and dTCR at the single cell level in peripheral blood eosinophils and cdT cells detected by in situ
hybridization using anti-sense and control sense probes specific for Vd2-Cd,V cI-JcP and for Vd1-Jd4 used as negative control.
doi:10.1371/journal.pone.0005926.g005
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Our results show that cdTCR surface expression was induced
upon incubation in the presence of a natural mycobacterial ligand
as well as following overnight culture. The molecular mechanism
underlying this later finding remains unknown. Our results
indicate that CD3e expression, both at mRNA and protein levels,
was consistently lower than cdTCR. Due to the requirement of
this CD3 subunit for surface expression of the receptor complex, it
is tempting to speculate that the very low CD3e expression
probably accounts for the low surface expression of the whole
complex on eosinophils although further experiments would be
required for a formal demonstration. This low receptor expression
Figure 6. Intraindividual variability between eosinophils and cdT cells in rearranged Vd1-Jd3 and Vd2-Cd TCR sequences. (A) TCR
locus organization with positions of the PCR probes used for sequence amplification. (B–C) Sequence alignment of Vd1-Jd3 (B) and Vd2-Cd (C) regions
analyzed from IGMT database, differentiated cdT cells and peripheral blood eosinophils obtained from the same allergic donors for. The two most
frequent sequences are presented for cdT cells. Grey boxes indicate mismatch.
doi:10.1371/journal.pone.0005926.g006
Eosinophil cdTCR Expression
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significant amounts of viable cdTCR
+ eosinophils following cell
sorting.
Eosinophils display a rearranged cdTCR with a more restricted
repertoire compared to cdT cells, further excluding the possibility
of lymphocyte contaminants in eosinophil preparations. Besides T
lymphocytes, dTCR rearrangements have only been reported in
malignant B lymphoblasts [43], NK cells [44] and in mixed-type
leukaemia retaining both T-lymphoid and myeloid characteristics.
Furthermore, presence of double positive Vd1
+Vd2
+ and equal
numbers of Vd1- and Vd2-expressing eosinophils in most of
normal donors suggests incomplete allelic exclusion as found in
some instances in cdT cells [45]. Direct cdTCR activation of
eosinophils by cdTCR/CD3-specific antibodies and selective
agonists induced eosinophil-specific responses. Release of such
myeloid-associated mediators and the scarcity of circulating cd T
cells further exclude the possibility that our results obtained using
highly purified eosinophils would be due to cdTCR expression by
contaminating lymphocytes.
Thus, mature eosinophils expressing lymphoid markers might
represent hitherto unattended cdTCR-expressing myeloid cells.
Our results might be in agreement with observations that myeloid-
derived plasmacytoid DC are able to express a ‘‘lymphoid
program’’ (RAG1, rearranged IgH genes) [46]. By contrast, in
the recently proposed myeloid-based model of haematopoiesis, T-
or B-committed progenitors would each keep a myeloid-
differentiation potential [47]. For instance, genetic reprogramming
from differentiated B cells to macrophages has been reported [48].
Further experiments are required to unravel by which mechanisms
eosinophils have acquired this lymphoid program. Of note,
eosinophils are found in human thymus [8]. Furthermore,
similarly to gut intraepithelial cdT cells, eosinophils are able to
undergo peripheral differentiation, for instance in allergic lungs
[49]. Investigating TCR expression by eosinophils in various
Figure 7. Specific mediator release upon CD3- or cdTCR-induced eosinophil activation. (A–C) Representative time course of ROS
production following eosinophil activation by immunobilized specific antibodies (A), BrHPP (B) or SBA stimulation (C). (A) Stimulation with
immobilized anti-CD3 (&), anti-cdTCR (X) or anti-Vd1( m) mAbs or control IgG1 (¤). (B) Stimulation by BrHPP 200 nM (#) 100 nM (&) and 50 nM (e)
or culture medium (¤). (C) Stimulation by SBA 500 mM( %)5 0mM( m) and 5 mM (X), culture medium (¤) or IgA/anti-IgA immune complexes (N). (D–F)
EPO release by eosinophils upon CD3 or cdTCR activation by specific antibodies (D) (n=6), BrHPP (E) (n=3) or SBA stimulation (F) (n=3). Results are
expressed in count per second (cps). (G) EDN release by eosinophils upon CD3 or cdTCR activation by specific antibodies (n=6). (H–I) Cytokine
production by eosinophils upon CD3 or cdTCR activation by specific antibodies or IgA/anti-IgA immune complexes. IFN-c production (H) (n=5–7)
and TNF-a production (I) (n=4–8). Results presented in panels E and F were obtained on different patients. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0005926.g007
Eosinophil cdTCR Expression
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animal models. Unfortunately, we were unable to detect cdTCR/
CD3 on mouse blood and tissue eosinophils. This is not extremely
surprising since mouse eosinophils are strikingly different from
human eosinophils, regarding their granular content [50] and
membrane expression of various immune receptors, in particular
IgE receptors [51] and IgA receptors [52]. Furthermore, cdT cells
also display significant differences between mouse and humans.
Indeed, a high proportion of skin lymphocytes express cdTCR in
mouse but not in human [53], while only human Vc9Vd2 are
responsive to phosphoantigens [54].
Our findings indicate that eosinophils might also contribute,
through cdTCR-dependent mechanisms, to immune defences in
tissues, where 90% eosinophils are located. One might speculate
that cdTCR/CD3 expression is higher in tissue than in blood
eosinophils, as previously reported for FceRI in a model of
‘‘humanized’’ mice where human FceRI was quantified and
increasingly expressed from blood to peritoneal cavity and spleen
eosinophils [9]. Tissue eosinophils are associated to granulomatous
diseases such schistosomiasis [55], Crohn’s disease [56] and
mycobacterial infections [39]. Eosinophils can damage cell wall
and lyse Mycobacterium tuberculosis in vitro[57]. Vc9d2 and Vd1
expression, rapid response to phosphoantigen ligands, as well as
BCG-induced activation so far represented hallmarks of cdT
lymphocyte-mediated cytotoxicity towards phosphoantigen-ex-
pressing mycobacteria [58]. Since tumors produce phosphoanti-
gens and are targeted by cdT lymphocytes [58], cdTCR-mediated
activation might thus contribute to the anti-tumoral activity of
eosinophils. Indeed, while cdT lymphocytes and NK cells display
granzyme B/perforin-mediated cytotoxicity, eosinophils addition-
ally possess a unique set of cationic proteins with a strong cytotoxic
potential [50]. Furthermore, tumor-associated tissue eosinophilia
(TATE) is considered by some authors as a marker of good
prognosis, including in colon carcinoma [59]. Anti-tumoral
activity of eosinophils should be considered in the context of
current development of innovative cancer immunotherapies,
based on synthetic phosphoantigens [60]. Indeed, due to their
high cytotoxic potential and despite their low cdTCR expression
in comparison to T cells, eosinophils might thus represent very
efficient ‘‘innate’’ effector cells in defence against targets bearing
cdTCR ligands, such as tumor cells, in particular when eosinophils
surround or infiltrate solid tumors.
Our work outlines a previously unexpected link between
eosinophils and cdT lymphocytes, which not only share the
expression of the cdTCR/CD3 complex but also some major
functions in innate immunity. It might also shed light on the
Figure 9. cdTCR-dependent tumor-cell killing by human eosinophils. (A–B) Induction of Colo205 killing by eosinophils and inhibition by an
anti-cdTCR blocking antibody. Percentage of AnnexinV
+ tumor cells in the presence or absence of eosinophils and blocking anti-cdTCR or isotype
control antibodies (n=5–7) at various time-points. Panel A represents the 60 min time-point. (C–D) Potentiation of eosinophil-mediated Colo205
killing by cdTCR ligands. (C) 50 mM SBA (n=7). (D) 20 mM TUBag (n=4). *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0005926.g009
Figure 8. Mycobacterium bovis-BCG-induced eosinophil activation. (A and E) Dose-dependent ROS production by BCG- (A) or TUBag (E)
activated eosinophils. BCG/eosinophil ratio: 20/1 ($), 10/1 (e), 5/1 (+) and 0/1 (2). (B and F) Dose-dependent EPO release by eosinophils activated by
different BCG/eosinophil ratios (n=3) (B) or TUBag concentrations (F). (C and G) Inhibition of BCG- (ratio 20/1 $) (C) or TUBag- (G) induced ROS
production by an anti-cdTCR blocking antibody 5 mg/ml (x) and 10 mg/ml (#) or an isotype control antibody (D). (D and G) Inhibition of BCG- (D) or
TUBag- (G) induced EPO production by an anti-cdTCR blocking antibody (5 and 10 mg/ml) or an isotype control antibody. Results are expressed as
DEPO cps values (values from medium stimulation are subtracted from values obtained with BCG stimulation for each antibody) (n=3). (E–F) *,
P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0005926.g008
Eosinophil cdTCR Expression
PLoS ONE | www.plosone.org 12 June 2009 | Volume 4 | Issue 6 | e5926molecular mechanisms of differentiation, diversity and function of
T-cell expressed cdTCR.
Materials and Methods
Ethics statement
Peripheral venous blood was obtained from healthy donors or
eosinophilic patients after written informed consent. Research
protocol was approved by the Comite ´ Consultatif de Protection
des Personnes dans la Recherche Biome ´dicale de Lille (France).
Cell purification and culture
Eosinophils were isolated as described [61] on Percoll followed
by negative selection using anti-CD16-coated microbeads. Purity
determined after cytospin and RAL555 staining was above 98%
and 100% for RNA analyses. Purified eosinophils were cultured
overnight at 37uC in complete RPMI without phenol red.
Neutrophils were obtained by positive selection with anti-CD16
coated microbeads. Purity was 99%. For RNA extraction, abTCR
lymphocytes from PBMC from normal donors were sorted after
staining with anti-abTCR-PE using FacsAria
TM cell sorter and
Diva
TM software (BD). Purity was 99%. cdTCR lymphocytes were
generated from PBMC (0.5610
6/ml) by culture in complete
RPMI 1640 medium with 200 nM bromohydrin pyrophosphate
BrHPP (Innate Pharma, Marseille) and 20 ng/ml rhIL-2 for
7 days. At that time, 50–70% cells were c9d2TCR
+ cells. For RT-
PCR and in situ hybridization, cdTCR
+ cells were further purified
using anti-cdTCR microbeads (Miltenyi).
Cord blood was obtained from the maternity unit of Lille
University Hospital. Mononuclear cells were isolated by Ficoll-
Hypaque density centrifugation. CD34
+ cells were purified using
CD34
+ isolation kit (Miltenyi). Purified CD34
+ cells were cultured
in complete medium supplemented with 2.5610
25 M b-mercap-
toethanol (b-ME) at 0.5610
6 cells/ml. Eosinophil differentiation
was induced upon addition of 50 ng/ml SCF, 1 ng/ml each GM-
CSF, IL-3 and IL-5 (Peprotech).
Colo-205 colon carcinoma cell line was obtained from ATCC.
Cells were maintained in RPMI 1640 medium supplemented with
10% FCS, 10 mM L-Glutamine and 10 mg/ml Gentamycin.
Flow cytometry
Antibodies and isotype controls used for flow cytometry (origin,
clone, working dilution or concentration) are listed in Table S1.
Anti-EPO (AHE) and anti-MBP2 [62] (a kind gift from Dr. D
Plager, Mayo Clinic, Rochester) were biotinylated using biotin-
sulfosuccinimidyl ester (Molecular Probes) according to manufac-
turer’s instructions and used at a 1:100 dilution. Samples were
analysed on a FACSCalibur
TM using CellQuest
TM software (BD).
Multiple staining experiments are represented as color density
plots [63] with linear scales used for both forward (FSC) and side
scatter (SSC) and logarithmic scales used for fluorescence
parameters (Log density: 50%).
Intracellular staining was performed after fixation of purified
eosinophils, neutrophils or PBMC (2610
5) with 2% paraformal-
dehyde and permeabilization with 0.01% saponin in PBS. After
blocking of non-specific binding with 5 ml mouse serum for
10 min, cells were incubated with anti-CD3-FITC, anti-abTCR-
FITC, anti-cdTCR-FITC or anti-CD8-FITC or corresponding
isotype controls for 30 min in the presence of saponin.
Following incubation for 2 h with or without TUBag-1 [36]
(40 nM) in RMPI 1640 or after overnight culture, purified blood
eosinophils were gated prior to the analysis, on the basis of their
FSC and SSC characteristics in order to exclude dead cells
(Figure 1B). Within PBMC fraction, monocytes and lymphocytes
were gated on the basis of their FSC and SSC characteristics prior
to the analysis. Quadrants were set on samples after double
staining with FITC- or APC- and PE- or biotin-conjugated control
isotype antibodies. At least 10
4 events were acquired per sample.
For double and triple staining, cultured peripheral eosinophils
were preincubated with 5% human serum albumin (HSA) for
30 min at 4uC and labelled for membrane receptor with the
relevant fluorochrome-conjugated antibodies. After washing, cells
were fixed 10 min with 2% paraformaldehyde at 4uC and
permeabilized for 10 min at room temperature (RT) with 0.01%
saponin in PBS-1% BSA. Non-specific binding was blocked with
5 ml mouse serum for 10 min. Purified peripheral blood
eosinophils were further identified by incubation with biotinylated
anti-EPO or anti-MBP or isotype control for 30 min and
streptavidin-PE (Molecular Probes) (1:200) for 20 min in the
presence of saponin. Neutrophils were identified by intracellular
staining with anti-MPO-PE following an identical procedure.
Monocytes and T lymphocytes were identified by staining with
anti-CD14-PE, anti-abTCR or anti-cdTCR respectively.
Immunofluorescence and confocal microscopy
Purified eosinophils were cytocentrifuged, fixed in 4% parafor-
maldehyde, washed in 0.05 M PBS. Fixation was stopped with
0.1 M glycine for 4 min and 50 mM NH4Cl pH 7.4 for 15 min.
After each incubation step, cytospins were washed for 10 min in
PBS. Cells were incubated with PBS-3% BSA-5% HSA for
30 min and, after one PBS wash, with 10% decomplemented
donkey serum (Jackson ImmunoResearch). Cytospins were then
incubated overnight at 4uC in a humid chamber with goat
antibodies specific for CD3e, CD3f, CD3c, CD3d, aTCR,
bTCR, cTCR, dTCR (Santa Cruz) or with goat IgG (Jackson
ImmunoResearch) in PBS-BSA-HSA (40 mg/ml). After washing in
PBS-0.1% BSA, cells were incubated with biotinylated donkey
anti-goat IgG (Jackson ImmunoResearch) (1:200) in PBS-BSA-
HSA for 2 hours, followed by streptavidin-Texas Red (Molecular
Probes) (1:500) in PBS-3% BSA for 1 hour. Final washes were with
PBS-0.1% BSA- 0.02% Tween 20 for 2610 min and with PBS for
10 min. For immunofluorescence, DNA was stained with Hoechst
33342 (Invitrogen) (1:1000), immediately prior to cytospin
mounting in Fluoromount G (Southern Biotechnologies).
For conventional immunofluorescence a Leica DM-RB micro-
scope equipped for epifluorescence with a 100 W mercury lamp
was used. Filter and dichroic mirror sets were TX2 for Texas Red
and A for Hoechst 33342. Images were acquired with a 10061.32
NA oil immersion objective, a Photometrics Cool SNAP
TM
camera using RSImage
TM software (Roper Scientific). Samples
were analysed by confocal microscopy using a DM-IRE2 inverted
microscope with SP2-AOBS scan-head (Leica) at the Imaging
Facility of Institut Pasteur de Lille. Excitation was performed at
543 nm for Texas Red. Fluorescence emission wavelengths pass
bands were selected between 581 and 621 nm according to the
emission spectral analysis. Excitation power was between 100 and
400 mW. Acquisitions were performed using a 10061.4 NA oil
immersion objective. 3D pre-treatment, analysis and edition were
performed with Edit3D (free software, Y. Usson, GDR2588,
CNRS, France). Analysis and editing was performed on Photo-
shop (Adobe).
Surface immunoprecipitation
Surface labelling and co-immunoprecipitation was performed as
previously described for cd T cells [64]. Purified human
eosinophils or differenciated cdT cells were washed and then
resuspended in PBS (pH 8.0) at 3.10
7 cells/ml at room temper-
ature. Surface biotinylation was performed for 30 min at room
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nology). Cells were washed three times with PBS containing
100 nM glycine and once in PBS.
Labelled cells were lysed in a buffer containing 20 mM Tris
(pH 7.5), 150 mM NaCl, 1 mM EDTA, protease inhibitors and
1% Brij 97 (Sigma-Aldrich). Lysates were cleared by centrifugation
for 15 min at 12,000 g and sequentially incubated at 4uC in the
presence of Protein-G Sepharose (Gamma bind Plus Sepharose,
Pharmacia), Protein G Sepharose-bound normal mouse IgG
(Jackson Immunoresearch) and Protein G Sepharose-bound anti-
cdTCR. Immunoprecipitated samples were washed three times
with lysis buffer then boiled in reducing sample buffer (30 mM
Tris, pH 6.8, 5% glycerol, 2% SDS, 2.5% b-mercaptoethanol,
0.1% bromophenol blue). Material was run on 14% polyacryl-
amide gels. Material corresponding to the total and to 1/10
th of
the material was loaded for eosinophils and cdT cells respectively.
Following separation, proteins were transferred to PVDF mem-
brane (Biorad). Blots were developed using ABC-HRP (Vector
Laboratories) and the enhanced chemiluminescence (ECL) plus
Western blot detection system (Amersham).
PCR analysis
Total RNA was isolated using the RNeasy mini kit (Qiagen)
from 10
7 purified cells and reverse transcription was performed
using SuperScript
TMRT (MMLV 200 U/ml) (Invitrogen). cDNA
was amplified using primers (Proligo) (20 pmoles/ml) listed in
Table S2. PCR were run for 40 cycles (1 min at 95uC, 1 min
annealing and 1 min at 72uC) using Taq polymerase (Bioprobe).
Real time PCR
Total RNA was prepared from eosinophils by guanidium/CsCl
centrifugation method. Briefly, purified eosinophils were pelleted
by centrifugation and then lysed in 4 M guanidium isothiocyanate,
1 mM EDTA, 25 mM sodium acetate, 4.9% b-mercaptoethanol,
68 mM N-lauryl sarcosine. Lysate was drawn through a 20G
needle. RNA was obtained by ultracentrifugation (28000 rpm,
20 h, and 20uC) through a CsCl gradient. RNA pellet was washed
twice and dissolved in water and precipitated overnight at 220uC
with ethanol 70% and sodium acetate 0.08 M. After centrifugation
(10000 rpm, 45 minutes at 4uC), RNA was washed twice in
ethanol 70%, resuspended in water and store at 280uC until use.
RNA from cd T cells and Colo205 cells was prepared using
RNeasy mini-spin columns (Qiagen, UK) according to the
manufacturer’s instructions. All samples were quantified by
absorbance measurement at 260 nm on a spectrophotometer
(Biorad), and RNA quality was checked by running samples on
1.5% agarose gel in RNA loading buffer (Sigma).
Total RNA was first submitted to DNAse I (Invitrogen)
treatment (15 min at room temperature), and cDNA was
generated using Superscript II reverse transcriptase (Invitrogen)
according to the manufacturer instructions. Samples were
analyzed by quantitative real-time PCR, performed according to
manufacturer’s protocol, using SYBR Green PCR Master Mix
(Applied Biosystems) and the ABI Prism 7000 Sequence Detection
System (Applied Biosystems). Primers were designed using the
Primer3 Website and are listed on Table S2.
Samples were run in triplicate in a reaction volume of 25 ml.
Amplification was carried out for 40 cycles, with denaturation at
95uC for 10 min during the first cycle and subsequently for
15 seconds, annealing and extension for 1 minute at 60uC. A
dissociation temperature gradient was included at the end of the
run. Gene expression was normalized according to GAPDH
expression. Relative gene expression was calculated with the
2
2DDCT method [65].
TCR repertoire analysis
Qualitative analysis of CDR3 length for Vc9-Jc1/2, Vc9-JcP
and Vd2-Cd families was performed in triplicate on eosinophils and
in cd T cells from the same donor (TcLand, Nantes, France) [66].
Briefly, cDNA was amplified by PCR using a Cc or Cd reverse
primer and Vc9o rV d2-specific forward primers, respectively. The
amplifications were performed in a 384-Well GeneAmpH PCR
System 9700 (Applied Biosystems, Foster City, CA). Briefly, each
amplification product was used for an elongation reaction using a
dye-labeled Jc specific-labelled primer for the rearrangement
analysis and Cd labeled primer for the d chain analysis, then heat
denatured, loaded at least in duplicate onto a sequencing analyzer
(48-capillary 3730 DNA Analyzer - Applied Biosystems). Then,
GeneMapper software (Applied Biosystems) was used to display the
distribution profiles of CDR3 lengths, in amino acids, of the
amplified and elongated products.
cdTCR junctional sequences analysis
Vd1-Jd3 and Vd2-Cd amplification products (400 bp) were
cloned into a TA vector (pCR-TOPO, Invitrogen) using standard
protocols. For each rearrangement, sequencing was performed on
5 randomly picked clones. TCR sequences were obtained from the
IMGT website (imgt.cines.fr). Sequence alignments were per-
formed using DNAstar software. GeneBank sequence accession
numbers are: FJ890312 and FJ890313 respectively.
In situ hybridisation
PCR products, amplified from purified cdTCR lymphocyte
RNA, and corresponding to VcI-JcP, Vd2-Cd and Vd1-Jd4
rearrangements were cloned into the pCRII-TOPO vector (Invitro-
gen). Clones were isolated and sequenced on both strands. Clones
corresponding to the published sequence were used to generate
hybridization probes. Sense and anti-sense probes were synthesised
from linearised plasmids using 350 mM digoxigenin-UTP (Roche)
and SP6 or T7 polymerases as described [67]. In situ hybridisation
was performed using a Discovery automat and corresponding kits
(Ventana Medical Systems). Slides were incubated in EZprep buffer
before processing with a standard RiboMap Kit. Slides were pre-
treated 30 min with CC2 buffer, then 20 min with protease 3,
followed by 6 h hybridization with sense or anti-sense probes
(100 ng/slide). Slides were then washed twice 10 min in 26SSC at
60uC, twice 10 min in 0.16SSC at 60uC. Slides were incubated for
30 min with a mouse anti-digoxigenin antibody (Jackson Immu-
noResearch) and then for 30 min with a rabbit anti-mouse antibody
before treatment with UltraMap kit. Labelling was detected after a
150 min (Vd2-Cd), 110 min (VcI-JcP) or 90 min (Vd1-Jd4)
incubation in the presence of NBT/BCIP substrate. Slides were
counterstained for 1 h with Nuclear Fast Red and mounted in
permanent mounting medium (Vector).
ROS production and EPO release
ROS production and EPO release were measured as described
[61]. Wells were coated with 10 mg/ml anti-mouse IgG F(ab’)2
(Sigma) for 2 h at 37uC, followed by incubation with 10 mg/ml
anti-CD3, anti-cdTCR, anti-Vd1or isotype control mouse IgG1
for 2 h at 37uC. Eosinophils (2610
6/ml) were added in the
presence of luminol (8.3 mg/ml). Alternatively, eosinophils were
stimulated with 50–200 nM BrHPP, 5–50 mM sec-butylamine
(SBA) (Sigma) or IgA/anti-IgA immune complexes (incubation
with 7.5 mg/ml secretory IgA for 1 hr then by addition of 10 mg/
ml anti-IgA). Chemiluminescence was measured at 37uC for
5 sec/timepoint with a luminometer (Victor
2TM Wallac). For EPO
release, supernatants (50 ml) were transferred into a microtiterplate
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25M) (Roche Diagnos-
tics) and H2O2 were injected.
EDN and cytokine release
Eosinophils (2610
6/ml) were activated with the same stimuli as
for ROS production. After 18 h culture, supernatants were
collected. EDN levels were measured by specific ELISA (MBL).
The lower detection limit was 0.62 ng/ml. IFNc and TNFa
cytokines were measured by specific ELISA (Diaclone). Detection
limit was 5 pg/ml for IFNc and 8 pg/ml for TNFa.
Activation with Mycobacteria
Mycobacterium bovis-BCG Pasteur strain was obtained from Dr C.
Locht (Inserm U629, Institut Pasteur de Lille, France) and was
grown in Sauton medium at 37uC. Eosinophils were incubated
with various BCG numbers (Eosinophil/BCG: 20/1, 10/1 and 5/
1). ROS and EPO release were determined as described above.
For inhibition experiments, eosinophils (20/1 ratio) were incubat-
ed with a blocking anti-cdTCR mAb (10 mg/ml) or isotype control
for 30 min at 37uC, before BCG addition.
Tumor cell apoptosis
Colo 205 cells were labelled with 10 mM PKH26 (Sigma)
according to manufacturer’s instructions. Then, eosinophil-
mediated cytotoxicity against PKH-26-labelled Colo-205
(10 mM) was measured in complete medium at 1.6610
4 targets/
well into U-bottom plates containing eosinophils (25:1 Effector:-
Target ratio) [61]. After different time points, apoptosis was
measured by flow cytometry after annexinV-FITC staining
(Pharmingen) for 15 min at RT. For inhibition experiments,
blocking antibodies against cdTCR or isotype-matched control
(10 mg/ml) were added to eosinophils immediately prior to the
incubation in the presence of targets. In some experiments,
eosinophils were preincubated for 30 min with 50 mM SBA or
20 mM TUBAg 1 before addition to the target cells.
Statistical analysis
Individual data or mean6S.E.M values were presented. All
statistical analyses were performed using SPSS software. Normal-
ity of data samples was assessed with the Normality test of Shapiro
and Wilk. Then parametric paired-samples Student’s t-test was
used to compare variables and the one-tailed statistical significance
level was as represented on Figures.
Supporting Information
Figure S1 Gating strategy and specific identification of purified
peripheral blood eosinophils in flow cytometry analysis. (A–B)
Gating of purified peripheral blood eosinophils on forward and
side scatter parameters immediately after purification. (A)
Ellipsoids circle the analyzed population. (B). Specificity of
eosinophil identification by intracellular detection of EPO, MBP
or MPO using PE- or biotin-conjugated specific antibodies (grey
shaded histograms). Staining on purified neutrophils as well as
gated lymphocytes and monocytes from purified PBMC is shown
as control. Staining with control isotype matched antibodies is
represented in white histograms.
Found at: doi:10.1371/journal.pone.0005926.s001 (6.41 MB TIF)
Figure S2 Surface expression of CD3, cdTCR, Vgamma9,
Vdelta2,Vdelta1, abTCR, CD8 and NKG2D detected by flow
cytometry in double staining on immune cell populations. (A) In
vitro-generated BrHPP-induced gamma9 delta2 TCR
+ lympho-
cytes. (B) Scatter-gated lymphocytes from PBMC. (C) Scatter-gated
monocytes from PBMC. (D) CD16
+-purified blood neutrophils.
Staining with control isotype matched antibodies is represented.
Found at: doi:10.1371/journal.pone.0005926.s002 (4.23 MB TIF)
Figure S3 Surface expression of cdTCR/CD3 complex by
human eosinophils following induction by a mycobacterial cdTCR
ligand. (A–B) CD3, cdTCR, abTCR and CD8 surface expression
on EPO
+-purified peripheral blood eosinophils incubated with
culture medium (A) or with 40 nM TubAg for 2 h (B). Staining
with control isotype matched antibodies is represented.
Found at: doi:10.1371/journal.pone.0005926.s003 (3.02 MB TIF)
Figure S4 Surface expression of CD3, cdTCR and CD8 on
cord blood-derived eosinophils. Eosinophils derived from CD34
+
cord blood cells (day 21) were analysed for CD3, cdTCR and CD8
cell surface expression after gating on EPO
+ cells. Staining with
control isotype antibodies is represented.
Found at: doi:10.1371/journal.pone.0005926.s004 (1.28 MB TIF)
Table S1 List, and characteristics of antibody used in this
manuscript. Mb: Membrane staining. IC: Intracellular staining
Found at: doi:10.1371/journal.pone.0005926.s005 (0.06 MB
DOC)
Table S2 Gene-specific primer sequences
Found at: doi:10.1371/journal.pone.0005926.s006 (0.04 MB
DOC)
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